Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 7/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.69 |
| ▸ | MEN1 | O00255 | 4/20 | 0.66 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.66 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.65 |
| ▸ | MAPT | P10636 | 3/20 | 0.65 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.65 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.65 |
| ▸ | HTT | P42858 | 1/20 | 0.65 |
| ▸ | RAB9A | P51151 | 3/20 | 0.59 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.57 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.56 |
| ▸ | NPC1 | O15118 | 2/20 | 0.55 |
| ▸ | THRB | P10828 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14962804 | 0.90 | HPGD (0.81) | HPGDALDH1A1MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL1976948 | 0.83 | HPGD (0.71) | HPGDALDH1A1MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL764569 | 0.83 | HPGD (0.71) | HPGDALDH1A1MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL22854085 | 0.83 | HPGD (0.71) | HPGDALDH1A1MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL6607271 | 0.82 | ALDH1A1 (0.71) | HPGDALDH1A1MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL29349031 | 0.82 | HPGD (0.71) | HPGDMEN1KMT2ASMN1; SMN2MAPT | |
| SCHEMBL5206026 | 0.81 | HPGD (0.75) | HPGDALDH1A1MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL2098410 | 0.81 | MTNR1A (0.70) | HPGDALDH1A1MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL2091479 | 0.81 | HPGD (0.70) | HPGDALDH1A1MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL853933 | 0.81 | HPGD (0.70) | HPGDALDH1A1KMT2ASMN1; SMN2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4539840-A1 | KINASE MODULATORS AND METHODS OF USE THEREOF | Neuron23, Inc. (US) | 2025-04-23 | — | — | EP | disclosed |
| CN-119730846-A | Kinase modulators and methods of use thereof | 神经元23公司 | 2025-03-28 | — | — | CN | disclosed |
| WO-2023244788-A9 | KINASE MODULATORS AND METHODS OF USE THEREOF | NEURON23, INC. (US) | 2024-09-12 | — | — | WO | disclosed |
| US-20240025906-A1 | KINASE MODULATORS AND METHODS OF USE THEREOF | SUNDANCE BIOSCIENCES, INC. | 2024-01-25 | — | — | US | disclosed |
| US-20240025906-A1 | KINASE MODULATORS AND METHODS OF USE THEREOF | SUNDANCE BIOSCIENCES, INC. | 2024-01-25 | — | — | US | disclosed |
| WO-2023244788-A1 | KINASE MODULATORS AND METHODS OF USE THEREOF | NEURON23, INC. (US) | 2023-12-21 | — | — | WO | disclosed |
| EP-3421467-A1 | 5-PHENYLAZAINDOLE DERIVATIVE HAVING AMPK ACTIVATING EFFECT | Shionogi & Co., Ltd (JP) | 2019-01-02 | — | — | EP | disclosed |
| WO-2017146186-A1 | 5-PHENYLAZAINDOLE DERIVATIVE HAVING AMPK ACTIVATING EFFECT | 塩野義製薬株式会社 | 2017-08-31 | — | — | WO | disclosed |
| US-7871982-B2 | Lincomycin derivatives and antimicrobial agents comprising the same as active ingredient | MEIJI SEIKA KAISHA, LTD. (JP) | 2011-01-18 | — | — | US | disclosed |
| US-20090156512-A1 | potent activity against resistant pneumococci | MEIJI SEIKA KAISHA, LTD. (JP) | 2009-06-18 | — | — | US | disclosed |
| EP-1970377-A1 | LINCOMYCIN DERIVATIVE AND ANTIBACTERIAL AGENT CONTAINING THE SAME AS ACTIVE INGREDIENT | MEIJI SEIKA KAISHA LTD. (JP) | 2008-09-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156512-A1 | potent activity against resistant pneumococci | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, NAT1, NPM1 | HPGD 2051/4885ALDH1A1 2976/4885MEN1 299/4885 |
| US-20240025906-A1 | KINASE MODULATORS AND METHODS OF USE THEREOF | TYK2, JAK1, JAK3 | HPGD 3842/4885ALDH1A1 4807/4885MEN1 3601/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.